In a recent evaluation, the Institute for Quality and Efficiency in Health Care (IQWiG) concluded that the cancer drug Pembrolizumab does not offer an additional advantage when combined with standard chemotherapy for treating adults with unresectable, non-epithelioid malignant pleural mesothelioma.
Assessment Overview
Commissioned by Germany’s Federal Joint Committee (G-BA), IQWiG scrutinized the effectiveness of Pembrolizumab paired with Pemetrexed and Platin chemotherapy against the established first-line therapy of Nivolumab combined with Ipilimumab. The evaluation relied on data from the pharmaceutical company’s dossier submitted on April 25, 2025.
Study Limitations Highlighted
IQWiG identified significant shortcomings in the KEYNOTE 483 study, which was pivotal to the dossier. The study initially compared Pembrolizumab alongside chemotherapy to chemotherapy alone and a monotherapy with Pembrolizumab. However, it failed to include the current standard treatment of Nivolumab and Ipilimumab, rendering its findings irrelevant for assessing additional benefits in the approved therapeutic context.
- The KEYNOTE 483 study did not compare Pembrolizumab with the established Nivolumab and Ipilimumab regimen.
- No randomized controlled trials met the necessary criteria to demonstrate a measurable benefit.
- IQWiG’s analysis highlighted the absence of relevant studies supporting an added advantage.
Despite the pharmaceutical company’s reliance on the KEYNOTE 483 trial, IQWiG determined that the lack of appropriate comparative data means Pembrolizumab combined with chemotherapy does not provide proven additional benefits over the existing first-line treatment.
This decision emphasizes the critical importance of robust comparative studies in the approval and reimbursement of cancer therapies. Patients and healthcare providers must consider these evaluations to make informed treatment choices. The absence of an additional benefit suggests that current standard therapies remain the most effective option for this patient group.
Moving forward, further research is essential to explore more effective treatment combinations for malignant pleural mesothelioma. It also underscores the need for pharmaceutical companies to design studies that align closely with current clinical standards to demonstrate true added value in their therapeutic offerings.
Healthcare stakeholders should stay informed about such assessments to ensure optimal patient outcomes and the efficient allocation of medical resources. This case serves as a reminder of the rigorous scrutiny that new treatments must undergo to validate their place in established treatment protocols.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
